Literature DB >> 9226729

Blunted serotonin-mediated activation of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome.

T G Dinan1, T Majeed, E Lavelle, L V Scott, C Berti, P Behan.   

Abstract

We examined 5HT1a-mediated ACTH release in patients with chronic fatigue syndrome (CFS) using a between-subjects design. Patients attending a specialist outpatient clinic for CFS, who fulfilled CDC criteria, together with age- and sex-matched healthy comparison subjects, were recruited. Subjects had a cannula inserted in a forearm vein at 0830 h and were allowed to relax until 0900 h, when baseline bloods for ACTH and cortisol were drawn. They were then given ipsapirone 20 mg PO and further blood for hormone estimation was taken at +30, +60, +90, +120 and +180 min. Baseline ACTH and cortisol levels did not differ between the two groups. Release of ACTH (but not cortisol) in response to ipsapirone challenge was significantly blunted in patients with CFS. We conclude that serotonergic activation of the hypothalamic-pituitary-adrenal axis is defective in CFS. This defect may be of pathophysiological significance.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9226729     DOI: 10.1016/s0306-4530(97)00002-4

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  11 in total

Review 1.  Drugs and HPA axis.

Authors:  Alberto Giacinto Ambrogio; Francesca Pecori Giraldi; Francesco Cavagnini
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 2.  Nutritional modulation of the intestinal microbiota; future opportunities for the prevention and treatment of neuroimmune and neuroinflammatory disease.

Authors:  Vincent C Lombardi; Kenny L De Meirleir; Krishnamurthy Subramanian; Sam M Nourani; Ruben K Dagda; Shannon L Delaney; András Palotás
Journal:  J Nutr Biochem       Date:  2018-04-19       Impact factor: 6.048

3.  Lymphocyte subset differences in patients with chronic fatigue syndrome, multiple sclerosis and major depression.

Authors:  M J Robertson; R S Schacterle; G A Mackin; S N Wilson; K L Bloomingdale; J Ritz; A L Komaroff
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

4.  Activity in the hypothalamo-hypophyseal-adrenocortical system on experimental induction of chronic fatigue syndrome.

Authors:  E E Fomicheva; T A Filatenkova; E G Rybakina
Journal:  Neurosci Behav Physiol       Date:  2010-02-10

Review 5.  Cancer-related fatigue in the elderly.

Authors:  A Giacalone; D Quitadamo; E Zanet; M Berretta; M Spina; U Tirelli
Journal:  Support Care Cancer       Date:  2013-07-13       Impact factor: 3.603

6.  An Etiological Model for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Authors:  Leonard A Jason; Matthew Sorenson; Nicole Porter; Natalie Belkairous
Journal:  Neurosci Med       Date:  2011-03-01

Review 7.  Chronic fatigue syndrome: an update.

Authors:  R J Shephard
Journal:  Sports Med       Date:  2001       Impact factor: 11.136

8.  Pediatric Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.

Authors:  Leonard A Jason; Kristen Barker; Abigail Brown
Journal:  Rev Health Care       Date:  2012-01-01

9.  Acute psychosocial stress-mediated changes in the expression and methylation of perforin in chronic fatigue syndrome.

Authors:  Virginia R Falkenberg; Toni Whistler; Janna R Murray; Elizabeth R Unger; Mangalathu S Rajeevan
Journal:  Genet Epigenet       Date:  2013-01-28

10.  An Adrenalectomy Mouse Model Reflecting Clinical Features for Chronic Fatigue Syndrome.

Authors:  Jin-Seok Lee; Yoo-Jin Jeon; Samuel-Young Park; Chang-Gue Son
Journal:  Biomolecules       Date:  2020-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.